OGNOrganon & Co.
$13.81+33% 1Y
$13.81
$5.6952 weeks$13.81
Latest close: a new 52-week highOct 9, 2026what changed →
The financials
Organon & Co. by the numbers
Organon & Co. (OGN) reported revenue of $1.56B in Q2 2026 (quarter ended Jun 30, 2026), down 2.3% from the same quarter a year earlier. That came with a gross margin of 54% and net income of $108M (6.9% of revenue). For the full year FY2025, revenue was $6.22B (−2.9% year on year) and net income $187M. Its largest product in Q2 2026 was Nexplanon Implanon NXT at $129M, 32% of the disclosed total, ahead of Hadlima at 14%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $1.56B | $1.59B | −2.3% |
| Gross profit | $847M | $874M | −3.1% |
| Net income | $108M | $145M | −26% |
| Diluted EPS | $0.40 | $0.56 | −29% |
| Product | Revenue | Share |
|---|---|---|
| Nexplanon Implanon NXT | $129M | 32% |
| Hadlima | $55M | 14% |
| Renflexis | $44M | 11% |
| Vtama | $34M | 8.5% |
| Dulera | $30M | 7.5% |
| Follistim AQ | $17M | 4.3% |
| Other Respiratory | $16M | 4.0% |
| Other Womens Health | $15M | 3.8% |
| Bildvos Bilprevda | $14M | 3.5% |
| Other Biosimilars | $10M | 2.5% |
| Nuva Ring | $9.0M | 2.3% |
| Ontruzant | $5.0M | 1.3% |
| Other Non Opiod Pain Bone And Dermatology | $4.0M | 1.0% |
| Cozaar Hyzaar | $2.0M | 0.5% |
| Ganirelix Acetate Injection | $2.0M | 0.5% |
| Other Sundry Established Brands | $2.0M | 0.5% |
| Propecia | $2.0M | 0.5% |
| Singulair | $2.0M | 0.5% |
| Zetia | $2.0M | 0.5% |
| Clarinex | $1.0M | 0.3% |
| Fosamax | $1.0M | 0.3% |
| Other Cardiovascular | $1.0M | 0.3% |
| Vytorin | $1.0M | 0.3% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $398.0M (+11%)
Other Biosimilars grew +233% year on yearOther Sundry Products -100% year on year
Segment Latestquarter on quarteryear on year
- Nexplanon Implanon NXT$129.0M$129.0Mquarter on quarter +1.6%year on year -21%+1.6%-21%
- Hadlima$55.0M$55.0Mquarter on quarter +7.8%year on year +53%+7.8%+53%
- Renflexis$44.0M$44.0Mquarter on quarter +4.8%year on year -4.3%+4.8%-4.3%
- Vtama$34.0M$34.0Mquarter on quarter +48%year on year +17%+48%+17%
- Dulera$30.0M$30.0Mquarter on quarter +30%year on year -6.3%+30%-6.3%
- Follistim AQ$17.0M$17.0Mquarter on quarter -19%year on year -43%-19%-43%
- Other Respiratory$16.0M$16.0Mquarter on quarter +45%year on year +45%+45%+45%
- Other Womens Health$15.0M$15.0Mquarter on quarter -12%year on year +7.1%-12%+7.1%
- Bildvos Bilprevda$14.0M$14.0Mquarter on quarter n/ayear on year n/an/an/a
- Other Biosimilars$10.0M$10.0Mquarter on quarter -9.1%year on year +233%-9.1%+233%
- Nuva Ring$9.0M$9.0Mquarter on quarter +50%year on year +29%+50%+29%
- Ontruzant$5.0M$5.0Mquarter on quarter +25%year on year 0.00%+25%0.00%
- Other Non Opiod Pain Bone And Dermatology$4.0M$4.0Mquarter on quarter +33%year on year 0.00%+33%0.00%
- Cozaar Hyzaar$2.0M$2.0Mquarter on quarter 0.00%year on year 0.00%0.00%0.00%
- Ganirelix Acetate Injection$2.0M$2.0Mquarter on quarter 0.00%year on year -33%0.00%-33%
- Other Sundry Established Brands$2.0M$2.0Mquarter on quarter -33%year on year -33%-33%-33%
- Propecia$2.0M$2.0Mquarter on quarter +100%year on year +100%+100%+100%
- Singulair$2.0M$2.0Mquarter on quarter 0.00%year on year 0.00%0.00%0.00%
- Zetia$2.0M$2.0Mquarter on quarter +100%year on year +100%+100%+100%
- Clarinex$1.0M$1.0Mquarter on quarter 0.00%year on year 0.00%0.00%0.00%
- Fosamax$1.0M$1.0Mquarter on quarter n/ayear on year n/an/an/a
- Other Cardiovascular$1.0M$1.0Mquarter on quarter 0.00%year on year 0.00%0.00%0.00%
- Vytorin$1.0M$1.0Mquarter on quarter 0.00%year on year 0.00%0.00%0.00%
- Arcoxia$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Atozet$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Brenzys$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Diprospan$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Emgality Ravvow$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Jada$0.00$0.00quarter on quarter -100%year on year -100%-100%-100%
- Marvelon Mercilon$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Nasonex$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Other Sundry Products$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
- Proscar$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
- Rosuzet$0.00$0.00quarter on quarter n/ayear on year n/an/an/a
On our screens:Cheap stocks by free cash flow yield
Drug Manufacturers, General
Ranks #4 of 7 by RyuScore